SYS6010

SYS6010 is an investigational agent whose form is not stated in the registry developed by CSPC Megalith Biopharmaceutical and CSPC ZhongQi Pharmaceutical Technology. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SYS6010will be administrated on a 14-day cycle. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT06927986 (Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）), in non-small-cell lung cancer and head and neck squamous cell carcinoma. The largest, NCT07241936, plans to enrol 444 participants with primary completion expected 2027-10-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.